68 Integrative Biomarkers Analysis from the Phase 3 CheckMate 914 Trial of Nivolumab Plus Ipilimumab or Nivolumab Versus Placebo for Adjuvant Clear Cell Renal Cell Carcinoma (Ccrcc)
Regular and Young Investigator Award Abstracts（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined